A PYMNTS Company

US: Senate panel probing Valeant on pharm pricing

By  |  November 4, 2015

A US Senate panel on Wednesday launched a bipartisan probe into pharmaceutical pricing, seeking documents from four drugmakers including Valeant Pharmaceuticals and Turing Pharmaceuticals, companies embroiled in controversy over price hikes on lifesaving drugs.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The Senate’s Special Committee on Aging also requested information from Retrophin Inc and Rodelis Therapeutics, according to a statement from the panel’s Republican Chairwoman Susan Collins and Claire McCaskill, its top Democrat.

    Also on Wednesday, Democratic members of a US House of Representatives investigative committee asked Republicans to call a vote to subpoena Valeant and Turing.

    These Democratic leaders called for an investigation of drug prices in September, emboldened by press reports of a more than 5000 percent overnight increase in a toxoplasmosis drug made by Turing and a more than 600 percent increase in a blood pressure treatment from Valeant.

    That investigation, along with news that Democratic Presidential candidate Hillary Clinton found the increases “outrageous” and the release of her plan to restrict drugmaker profits, has hurt their stock prices. Drugmakers and their defenders say drugs are priced to help enable discovery and development of innovative new treatments.

    Full content: Headlines & Global News

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.